Bruker Daltonics Inc. Announces U.S. Collaborations for the Clinical Validation of Rapid, Highly Specific and Low-Cost Microbial Identification by Proteomic Fingerprinting Using its MALDI Biotyper

PHILADELPHIA--(BUSINESS WIRE)--At the 109th General Meeting of the American Society for Microbiology, Bruker Daltonics announced collaborations in the United States for the clinical validation of its MALDI Biotyper workflow for microorganism identification. The MALDI Biotyper has recently obtained the IVD-CE Mark, and is currently for Research Use Only (RUO) outside of the European Union.

Back to news